Linda Kolstad
Forskningsassistent vid Institutionen för medicinsk biokemi och mikrobiologi; Infektioner och immunitet; Åke Lundkvist
- E-post:
- linda.kolstad@imbim.uu.se
- Besöksadress:
- BMC
Husargatan 3
752 37 UPPSALA - Postadress:
- Box 582
751 23 UPPSALA
Mer information visas för dig som medarbetare om du loggar in.
Publikationer
Senaste publikationer
- Seroprevalence of tick-borne encephalitis virus and vaccination coverage of tick-borne encephalitis, Sweden, 2018 to 2019 (2024)
- Influenza-A mediated pre-existing immunity levels to SARS-CoV-2 could predict early COVID-19 outbreak dynamics (2023)
- Strict self-isolation did not protect Swedish cancer patients on active treatment from the risk of becoming seropositive for SARS-CoV-2 (2023)
- Reduced Binding between Omicron B.1.1.529 and the Human ACE2 Receptor in a Surrogate Virus Neutralization Test for SARS-CoV-2 (2023)
- Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in the Serum and Cerebrospinal Fluid of Patients With Coronavirus Disease 2019 and Neurological Symptoms (2022)
Alla publikationer
Artiklar
- Seroprevalence of tick-borne encephalitis virus and vaccination coverage of tick-borne encephalitis, Sweden, 2018 to 2019 (2024)
- Influenza-A mediated pre-existing immunity levels to SARS-CoV-2 could predict early COVID-19 outbreak dynamics (2023)
- Strict self-isolation did not protect Swedish cancer patients on active treatment from the risk of becoming seropositive for SARS-CoV-2 (2023)
- Reduced Binding between Omicron B.1.1.529 and the Human ACE2 Receptor in a Surrogate Virus Neutralization Test for SARS-CoV-2 (2023)
- Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in the Serum and Cerebrospinal Fluid of Patients With Coronavirus Disease 2019 and Neurological Symptoms (2022)
- COVID-19 seroprevalence and clinical picture in Swedish pediatric oncology and hematology patients (2022)
- Diagnostic Potential of a Luminex-Based Coronavirus Disease 2019 Suspension Immunoassay (COVID-19 SIA) for the Detection of Antibodies against SARS-CoV-2 (2021)
- Evaluation of Production Lots of a Rapid Point-of-Care Lateral Flow Serological Test Intended for Identification of IgM and IgG against the N-Terminal Part of the Spike Protein (S1) of SARS-CoV-2 (2021)
